CN107014992A - A kind of foundation for quantitatively detecting human blood type antibody concentration method - Google Patents
A kind of foundation for quantitatively detecting human blood type antibody concentration method Download PDFInfo
- Publication number
- CN107014992A CN107014992A CN201611006650.2A CN201611006650A CN107014992A CN 107014992 A CN107014992 A CN 107014992A CN 201611006650 A CN201611006650 A CN 201611006650A CN 107014992 A CN107014992 A CN 107014992A
- Authority
- CN
- China
- Prior art keywords
- reagent
- blood group
- antigen
- antibody
- klh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
It is clinical vitro detection reagent technique field the invention discloses a kind of anti-A of utilization immunoturbidimetry standard measure detection people, the method for anti-blood group antibody B concentration.Reagent includes reagent R1, reagent R2, reagent R3, standard items 1, standard items 2 applied in this method.Specific method is：The specific trisaccharide of Antigen of human blood group is coupled on KLH, it is prepared into KLH A or KLH B protein dry powders, the purity unicity that blood group antigens can effectively be improved, the permanence preserved, and the reagent R1 (active ingredient is KLH A) and reagent R2 (active ingredient is KLH B) through being prepared into using 0.01M pH7.4 PBS dissolvings have accurate sample concentration, most it is mixed with reagent R3 and detection sample at last, with that can quantify the concentration of blood group antibody in sample after standard control.Through being found compared with the conventional blood group antibody detection method of clinic, heretofore described method can quantify testing result, with intuitive and accurate feature, and the influence to testing result such as reagent stability, human factor can be effectively excluded, thus be conducive to popularization and application of the blood group antibody quantitative detecting method illustrated in the present invention in terms of clinical detection.
Description
Technical field
The present invention relates to a kind of utilization immunoturbidimetry standard measure detection human peripheral moderate resistance A, the side of anti-blood group antibody B concentration
Method, belongs to clinical vitro detection reagent technique field.
Background technology
Blood group antigens are as one of big antigen of human body three, and it is not distributed only on erythrocyte membrane, exists in the groups such as liver, kidney
Knit cell and Surface of Vascular Endothelial Cells.According to the similarities and differences of antigenic substance on erythrocyte membrane, the blood group point that International Society of Blood Transfusion announces
Just up to 30 kinds of type system, wherein ABO blood group system is widely used in human body as main and conventional blood grouping method
In terms of blood transfusion, organ transplant.
ABO blood group system includes four kinds of blood groups, i.e. A types, Type B, AB types and O-shaped.Four kinds of different blood group crowds are anti-in blood group
Difference in terms of former and blood group antibody is essentially consisted in：Blood group A antigen, bone-marrow-derived lymphocyte expression blood are expressed on the erythrocyte membrane of A type blood
Type B antigen-antibodies, blood plasma prestores certain density blood group B antigen-antibodies；Blood group B antigens, B are expressed on the erythrocyte membrane of Type B blood
Prestore certain density blood group A antigen antibody in Expressions In Lymphocytes blood group A antigen antibody, blood plasma；The erythrocyte membrane of AB type blood
Upper expression blood group A antigen and blood group B antigens, bone-marrow-derived lymphocyte are not expressed in blood group antigens antibody, blood plasma without the blood group antigens prestored
Antibody；Blood group antigens are not expressed on the erythrocyte membrane of O-shaped blood, bone-marrow-derived lymphocyte expression blood group A antigen antibody and blood group B antigens are anti-
Prestore certain density blood group A antigen antibody and blood group B antigen-antibodies in body, blood plasma.
At present, the patient numbers of organ transplant are waited to remain high always both at home and abroad, its main cause is groups compatible
The height of organ lacks.Based on this, the incompatible organ transplant of abo blood group (ABO blood group incompatibility
Organ transplantation, ABOi-OT) in global successful development, become and solve an organ origin weight in short supply
Want approach.And preoperative remove prestores blood group antibody and control postoperative blood group antibody concentration bounce-back in recipient's body, as influence ABOi-
OT major obstacle.Therefore, monitor and quantify detection ABOi organ transplants before and after blood group antibody concentration turn into ABOi-OT operation
The important evidence of solution formulation.
At present, the method for clinical labororatory's detection blood group antibody mainly has high performance liquid chromatography (HPLC) and brine media
Method, antiglobulin medium method, low ion polybrene medium method, micro-column gel detection card etc..Wherein, although HPLC is quantitative detection
Method, but because the equipment of needs is complicated and expensive, it is difficult to it is widely used in clinical labororatory；Remaining detection method --- especially
It is current clinical conventional micro-column gel detection card, is semi-quantitative detection method, it is difficult to which quantitative result is provided, and to detection
As a result judgement is easily influenceed by reagent stability, human factor etc..And the blood group antibody immunoturbidimetry used in the present invention
It is the specific binding reaction based on blood group antibody-blood group antigens, its immune complex formed has absworption peak in 340nm wavelength
Value.This method does not need expensive equipment, and can realize automation, high-volume Samples detection, meets what is applied in clinical detection
Basic demand.In addition, the specific trisaccharide of artificial synthesized blood group antigens is coupled into keyhole limpet hemocyanin in the present invention, it can be ensured that
Purity unicity, the certainty of concentration, the permanence preserved of detection reagent, more improve the method in terms of clinical detection
Popularization and application.
The content of the invention
For the deficiency of current clinical human blood type antibody concentration assay method, blood group is quantitatively detected the invention provides one kind
The method for detecting antibody concentration, compared with micro-column gel detection card, as a result more objectivity, is conducive to what is illustrated in the present invention
Popularization and application of the blood group antibody quantitative detecting method in terms of clinical detection.
1. agents useful for same of the present invention and composition
A kind of human blood type antibody quantitative detecting method based on immunoturbidimetry, it is characterised in that include reagent R1, reagent
R2, reagent R3, calibration object 1 and calibration object 2.PBS, 0.008- that wherein reagent R1 compositions are 0.01M pH 7.4
0.012mg/ml keyhole limpet hemocyanin coupling blood group A antigen (KLH-A)；Reagent R2 compositions delay for 0.01M pH 7.4 PBS
The keyhole limpet hemocyanin coupling blood group B antigens (KLH-B) of fliud flushing, 0.008-0.012mg/ml；Reagent R3 compositions are 0.01M pH
The PEG-8000 of 7.4 PBS, 0.15M NaCl, 40-60g/L.
KLH-A, KLH-B of the present invention are Alberta Innovates Techenology Futures companies
Synthesis, calibration object 1 (the anti-human blood group A antigen antibody reagent of mouse) and calibration object 2 (the anti-human blood group B antigen-antibodies reagent of mouse) are purchased from
Abcam companies.
2. blood group antibody quantitative detecting method is set up in the present invention
1. the specific binding site of Antigen of human blood group is the specific trisaccharide on erythrocyte membrane, this side chain shifts for glycosyl
Enzymatic specificity trisaccharide group is coupled to Band 3, the albumen of Band 4.5, kidney on albumen on cell membrane, such as erythrocyte membrane
VWF, PLVAP, PECAM1 albumen of tissue.Therefore, it is the purity and antigenicity of guarantee antigen, artificial synthesized blood group in the present invention
After A and B antigentic specificity trisaccharides, it is coupled on KLH albumen (KLH-A, KLH-B).
2. the conventional Antigen of human blood group antibody of detection is the anti-human blood group antigens antibody plasma of mouse, contain various kinds of cell culture
Liquid Proteins.Therefore, PAGE electrophoresis combination western-blotting technologies are used in the present invention, identifies and to analyze mouse anti-human
Blood group A, B antibody concentration, concrete operations and result are as follows：
The identification of blood group antibody effective ingredient in practice
By the 1 anti-human blood group A antigen antibody plasma of μ l mouse or the 4 anti-human blood group B antigen-antibodies blood plasma of μ l mouse through 8% gum concentration
After PAGE electrophoresis, 300mA constant current ice bath electricity turns 90min, and TBS washes film 5min × 3 time, sheep anti mouse IgM-HRP (1: 2000) normal temperature
40min is incubated, TBS washes film 10min × 2 time, ECL luminesceence analyses.
As a result as shown in figure 1, being deposited in the anti-human blood group A antigen antibody plasma of mouse and the anti-human blood group B antigen-antibody blood plasma of mouse
There was only the anti-human blood group A antigen antibody of mouse or the anti-human blood plasma B antigen-antibodies of mouse in a variety of non-IgM molecules, and in two parts of plasma antibodies
With sheep anti mouse IgM-HRP association reactions.
The analysis of effective ingredient concentration in blood group antibody reagent kit
Using BSA as standard items, 0.5 μ g, 1 μ g, 2 μ g, 4 μ g, 8 μ gBSA albumen, Cowes light blue dye are separated by electrophoresis by PAGE
Color and fully decolourize after, with each concentration BSA band gray values in PDQuest software analysis polyacrylamide gels, and set up
Protein content-gray value standard curve.On the basis of secondary, the 1 anti-human blood group A antigen antibody of μ l mouse or the 1 anti-human blood group B of μ l mouse are taken respectively
Antigen-antibody, the PAGE electrophoresis through 8% gum concentration and fully coomassie brilliant blue staining decolourize after, with PDQuest software analysis its
Gray value, and establishing criteria curve calculates the concentration of the anti-human blood group A antigen antibody of mouse and the anti-human blood group B antigen-antibodies of mouse.Every group
Data are in triplicate.
As a result as shown in Fig. 2 the coefficient correlation of BSA protein contents-gray value standard curve is 0.9952, Dependence Results can
Letter.Be computed analysis, the concentration of the anti-human blood group A antigen antibody of mouse and the anti-human blood group B antigen-antibodies of mouse be respectively 0.90 μ g/ μ l and
0.57μg/μl。
3. on the basis of the above results, the anti-human blood group B antigen-antibodies of mouse and KLH-B antigens are analyzed with immunoturbidimetry
Association rate curve, to determine optimal detection time, detecting instrument used is BioPhotometer Plus nucleic acid-proteins
Instrument (λ of the present invention340The measure of nm light absorption values is with this model instrument), concrete operations and result are as follows：
Under the conditions of checking current experiment, optimal light absorption value minute point.The present invention chooses actual R2 and calibration object 2
As measure object, to determine the optimum detection time point of the invention that should be taken.
First, 5 small test tubes are taken, often pipe adds physiological saline 0.1ml, 0.1ml standard items 2 is added in the 1st pipe, mixed
0.1ml is drawn afterwards and adds the 2nd pipe, the rest may be inferred, to the 5th pipe, finally discards 0.1ml.Then, returned to zero with 100 μ l reagent R2
Afterwards, the sample after 99 μ l reagent R2 is diluted with 1 μ l is mixed, since 3min, and detection biased sample per minute is in λ340nm
Light absorption value, until 10min.Every group of Data duplication three times, takes its average value to set up the anti-human blood group antigens antibody of mouse and antigen
Association rate curve.
As a result as shown in figure 3, the anti-human blood group B antigen-antibodies of mouse and KLH-B association rate reach maximum in 5min,
Association rate change afterwards is gradually reduced.Therefore, it is the combination situation of the more preferable reacting antigen-antibody of energy, the present invention will take
Detection time point is used as during 5min.Taken detection time point is consistent with relevant report.
4. further by formulating the anti-human blood group A antigen antibody of mouse and KLH-A, the anti-human blood group B of mouse with immunoturbidimetry
Antigen-antibody and KLH-B antibody concentration-light absorption value standard curve (antigen-antibody binding curve is in cubic function relation), specifically
Operation and result are as follows：
The combined standard curve of blood group A antigen antibody and blood group A antigen
First, 5 small test tubes are taken, often pipe adds physiological saline 0.1ml, 0.1ml standard items 1 is added in the 1st pipe, mixed
0.1ml is drawn afterwards and adds the 2nd pipe, the rest may be inferred, to the 5th pipe, finally discards 0.1ml.Then, returned to zero with 100 μ l reagent R1
Afterwards, the sample after 99 μ l reagent R1 is diluted with 1 μ l is mixed, after incubation at room temperature 5min, in λ340nmDetect its light absorption value.Every group
After Data duplication three times, its average value is taken to set up the combined standard curve of blood group A antigen antibody and blood group A antigen.
The combined standard curve of blood group B antigen-antibodies and blood group B antigens
First, 5 small test tubes are taken, often pipe adds physiological saline 0.1ml, 0.1ml standard items 2 is added in the 1st pipe, mixed
0.1ml is drawn afterwards and adds the 2nd pipe, the rest may be inferred, to the 5th pipe, finally discards 0.1ml.Then, returned to zero with 100 μ l reagent R2
Afterwards, the sample after 99 μ l reagent R2 is diluted with 1 μ l is mixed, after incubation at room temperature 5min, in λ340nmDetect its light absorption value.Every group
After Data duplication three times, its average value is taken to set up the combined standard curve of blood group B antigen-antibodies and blood group B antigens.
As a result as shown in Figure 4 and Figure 5, Fig. 4 is the anti-human blood group A antigen antibody of mouse and KLH-A combined standard curves, curve
Coefficient correlation is 0.9957, and real result is credible；Fig. 5 is the anti-human blood group B antigen-antibodies of mouse and KLH-B combined standard curves, song
The phase relation coefficient of line is 0.9966, and real result is credible.
5. finally compared with micro-column gel detection card, to verify that blood group antibody quantitative detecting method used is aligned in the present invention
The accuracy of blood group antibody concentration mensuration in ordinary person's peripheral blood.
Brief description of the drawings
The identification of anti-human blood group A, the B antigen-antibody of Fig. 1 mouse.(A) western- of the anti-human blood group A antigen antibody of mouse
Blotting is analyzed, Lane 1.Marks, Lane 2.PAGE analyses, Lane 3.western-blotting analyses, and secondary antibody is
Sheep anti mouse blood group antigens IgM-HRP (1: 2000)；(B) the western-blotting analyses of the anti-human blood group B antigen-antibodies of mouse,
Lane 1.Marks, Lane 2.PAGE are analyzed, and Lane 3.western-blotting analyses, secondary antibody is sheep anti mouse blood group antigens
IgM-HRP(1∶2000)。
Fig. 2 .BSA standard proteins concentration-gray value tracing analysis.(A) PAGE electrophoresis, Lane 1.0.5 μ gBSA,
The 4.4 5.8 μ g BSA of μ g BSA, Lane of μ g BSA, Lane of Lane2.1 μ g BSA, Lane 3.2；(B) BSA protein contents-gray scale
Value analysis
Fig. 3 blood group B antigens and the anti-human blood group B antigen-antibodies binding time speed-change curve of mouse
Fig. 4 human blood type Staphylococal Protein A antibody standard curve is analyzed
Fig. 5 human blood type B antigen-antibodies standard curve is analyzed
Embodiment
The of embodiment one is compared with micro-column gel detection card, blood group antibody concentration quantitative detection side used in the checking present invention
The accuracy of method.
1. micro-column gel detection card separately verifies the potency of blood group antibody in A, Type B human normal plasma.
First, 5 small test tubes are taken, often pipe adds physiological saline 0.1ml.0.1ml A types or Type B blood are added in the 1st pipe
Blood plasma, draws 0.1ml and adds the 2nd pipe, the rest may be inferred, to the 5th pipe, finally discard 0.1ml after mixing.Then, often pipe microtrabeculae coagulates
Add a certain amount of standard A type blood or Type B erythrocyte physiological saline suspension (3% dilution) and detection B blood group blood in glue detection card
Slurry or A type blood blood plasma, 37 DEG C of incubation 15min.In after 1000rpm centrifugations 10min, detection card, visual results are taken out.
2. immunoturbidimetry determines the concentration of blood group antibody in A, Type B human normal plasma
First, 5 small test tubes are taken, often pipe adds physiological saline 0.1ml.0.1ml A types or Type B blood are added in the 1st pipe
Blood plasma, draws 0.1ml and adds the 2nd pipe, the rest may be inferred, to the 5th pipe, finally discard 0.1ml after mixing.Then, with 100 μ l examination
After agent R2 zeroings, the sample after 99 μ l reagent R1 is diluted with 1 μ l is mixed, after incubation at room temperature 5min, in λ340nmDetect that it is inhaled
Light value.
As a result as shown in Table 1 and Table 2：
Blood group antibody in the micro-column gel of table 1. detection card and immunoturbidimetry analysis A type blood blood plasma
Blood group antibody in the micro-column gel of table 2. detection card and immunoturbidimetry analysis Type B blood blood plasma
Data display described in Tables 1 and 2, compared with micro-column gel detection card, with the doubling dilution of blood plasma, is immunized ratio
The ratio of two term reduction close to 2 times is presented in the data that turbid method is determined, and illustrates that immunoturbidimetry used can also react well in the present invention
The variation tendency of blood group antibody, and the concentration of blood group antibody in sample can be shown with the result of quantification, and can be in certain journey
The erroneous judgement that reagent stability, human factor etc. are caused to result is excluded on degree.
Claims (5)
1. a kind of human blood type antibody quantitative detecting method based on immunoturbidimetry, it is characterised in that include reagent R1, reagent
R2, reagent R3, calibration object 1 and calibration object 2.PBS, 0.008- that wherein reagent R1 compositions are 0.01M pH 7.4
0.012mg/ml keyhole limpet hemocyanin coupling blood group A antigen (KLH-A)；Reagent R2 compositions delay for 0.01M pH 7.4 PBS
The keyhole limpet hemocyanin coupling blood group B antigens (KLH-B) of fliud flushing, 0.008-0.012mg/ml；Reagent R3 compositions are 0.01M pH
The PEG-8000 of 7.4 PBS, 0.15M NaCl, 40-60g/L；Calibration object 1 is the anti-human blood group A antigen antibody examination of mouse
Agent；Calibration object 2 is the anti-human blood group B antigen-antibody reagents of mouse.
2. according to claim 1, the quantitative detection of human blood type antibody A is that formula formula is calculated and realized, its formula is：
Y=-21819x3+1644x2-0.9588x+0.0426, y represent concentration, and x represents light absorption value.
3. according to claim 1, human blood type antibody B quantitative detection is to be calculated and realized by formula, its formula is：
Y=-12735x3+1543.2x2-50.649x+0.5213, y represent concentration, and x represents light absorption value.
4. according to claim 1, it is characterised in that the blood group B in blood group A antigen, reagent R2 in described reagent R1
Antigen be respectively be coupled to the specific trisaccharide of blood group A antigen of keyhole limpet hemocyanin, the blood group B that is coupled to keyhole limpet hemocyanin resists
Former specificity trisaccharide.
5. according to claim 1, ratio when reagent R1 and reagent R3, reagent R2 and reagent R3 are used is divided into R1: R3
=5: 94, R2: R3=5: 94.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611006650.2A CN107014992B (en) | 2016-11-10 | 2016-11-10 | A kind of foundation of quantitative detection human blood type antibody concentration method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611006650.2A CN107014992B (en) | 2016-11-10 | 2016-11-10 | A kind of foundation of quantitative detection human blood type antibody concentration method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107014992A true CN107014992A (en) | 2017-08-04 |
| CN107014992B CN107014992B (en) | 2019-08-02 |
Family
ID=59439451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611006650.2A Expired - Fee Related CN107014992B (en) | 2016-11-10 | 2016-11-10 | A kind of foundation of quantitative detection human blood type antibody concentration method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107014992B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111766286A (en) * | 2020-07-09 | 2020-10-13 | 深圳兰度生物材料有限公司 | Method for detecting content of hybrid protein in collagen |
| CN115343485A (en) * | 2022-10-18 | 2022-11-15 | 天津德祥生物技术股份有限公司 | Application of blood group antigen-trisaccharide conjugate in blood group antibody detection |
| CN116868059A (en) * | 2022-10-18 | 2023-10-10 | 天津德祥生物技术股份有限公司 | Application of blood group antigen trisaccharide conjugate in blood group antibody detection |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1584595A (en) * | 2004-05-31 | 2005-02-23 | 广州伟仕科技有限公司 | External blood group and blood serum experimental determining method |
| CN101178410A (en) * | 2006-11-07 | 2008-05-14 | 上海血液生物医药有限责任公司 | Red corpuscle reagent box for reverse typing used for detecting human ABO blood type |
| CN101957366A (en) * | 2009-07-15 | 2011-01-26 | 英科新创(厦门)科技有限公司 | Human erythrocyte membrane antigen coated microsphere and application thereof |
| CN105137096A (en) * | 2015-08-27 | 2015-12-09 | 中国人民解放军总医院 | Kit used for blood group antibody detection and application thereof |
| CN105548572A (en) * | 2016-02-02 | 2016-05-04 | 潍坊三维生物工程集团有限公司 | Kit and method for detecting content of immune globulin D and application |
| CN105548573A (en) * | 2016-02-02 | 2016-05-04 | 潍坊三维生物工程集团有限公司 | Kit and method for detecting content of KAPPA light chain and application |
-
2016
- 2016-11-10 CN CN201611006650.2A patent/CN107014992B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1584595A (en) * | 2004-05-31 | 2005-02-23 | 广州伟仕科技有限公司 | External blood group and blood serum experimental determining method |
| CN101178410A (en) * | 2006-11-07 | 2008-05-14 | 上海血液生物医药有限责任公司 | Red corpuscle reagent box for reverse typing used for detecting human ABO blood type |
| CN101957366A (en) * | 2009-07-15 | 2011-01-26 | 英科新创(厦门)科技有限公司 | Human erythrocyte membrane antigen coated microsphere and application thereof |
| CN105137096A (en) * | 2015-08-27 | 2015-12-09 | 中国人民解放军总医院 | Kit used for blood group antibody detection and application thereof |
| CN105548572A (en) * | 2016-02-02 | 2016-05-04 | 潍坊三维生物工程集团有限公司 | Kit and method for detecting content of immune globulin D and application |
| CN105548573A (en) * | 2016-02-02 | 2016-05-04 | 潍坊三维生物工程集团有限公司 | Kit and method for detecting content of KAPPA light chain and application |
Non-Patent Citations (1)
| Title |
|---|
| 王军祥等: "灵长类动物ABO血型不合肾移植后超急性排斥反应模型的建立", 《中华器官移植杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111766286A (en) * | 2020-07-09 | 2020-10-13 | 深圳兰度生物材料有限公司 | Method for detecting content of hybrid protein in collagen |
| CN115343485A (en) * | 2022-10-18 | 2022-11-15 | 天津德祥生物技术股份有限公司 | Application of blood group antigen-trisaccharide conjugate in blood group antibody detection |
| CN116868059A (en) * | 2022-10-18 | 2023-10-10 | 天津德祥生物技术股份有限公司 | Application of blood group antigen trisaccharide conjugate in blood group antibody detection |
| CN116868059B (en) * | 2022-10-18 | 2024-04-05 | 天津德祥生物技术股份有限公司 | Application of blood group antigen trisaccharide conjugate in blood group antibody detection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107014992B (en) | 2019-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103604931B (en) | A kind of people's S100 protein assay reagent and preparation method | |
| CN107817354A (en) | A kind of chemiluminescence detection kit of interleukin 6 and preparation method thereof | |
| CN101735319B (en) | Monoclonal antibody against GP73 protein, preparation method and application thereof | |
| WO2016011852A1 (en) | Bladder tumor-associated antigen detection kit | |
| CN106468711A (en) | DCP sharp separation detection kit | |
| CN110514848A (en) | A kind of glycosylated hemoglobin antibody complex and glycosylated hemoglobin detection kit | |
| CN107014992A (en) | A kind of foundation for quantitatively detecting human blood type antibody concentration method | |
| CN109406778A (en) | The time-resolved fluorescence quantitative test paper item and its preparation method and application of ralstonia solanacearum in a kind of detection tobacco leaf | |
| CN106443018A (en) | Myoglobin monoclonal abzyme marking compound and preparation method thereof and detection test kit | |
| CN108169497A (en) | Human prolactin detection kit and preparation method and application | |
| CN102608325A (en) | Fatty acid-binding protein (H-FABP) determination kit (latex enhanced immunoturbidimetric assay) | |
| CN106918708A (en) | A kind of competition law turbid kit of latex enhancing immune transmittance for detecting insulin | |
| CN101178408A (en) | Apolipoprotein E ELISA reagent box and method of producing the same | |
| CN102367270B (en) | Preparation method of cyclosporin A haptin and enzymelinked immunosorbent quantitative detection kit of cyclosporin A | |
| CN106771152A (en) | A kind of kit of quick detection calprotectin | |
| CN107533053A (en) | L FABP method of immunity and the measure reagent for methods described | |
| CN107290545A (en) | β2-microglobulin solution, its preparation method and the application of a kind of stabilization | |
| CN107119023A (en) | The monoclonal antibody of the anti-human cardic fatty acid binding protein of resistance to aliphatic acid interference and its application | |
| CN106970226A (en) | The kit of the ECD concentration levels of HER 2 in a kind of measure human serum | |
| CN106771247A (en) | A kind of diagnostic kit of the microglobulins of β 2 | |
| CN106366199A (en) | Troponin I monoclonal antibody magnetic particles and preparation method thereof, and detection kit | |
| AU658604B2 (en) | Highly sensitive assay of tissue factor and kit therefor | |
| CN104833797B (en) | ELISA method of detecting bispecific antibody MSBODY and application of the method | |
| CN115128282B (en) | Fibronectin detection kit and detection method thereof | |
| CN102369441B (en) | Immunoassay method and reagent therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190802 Termination date: 20211110 |